Richard Alm

Richard joined CARB-X in 2019 following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company where he supported the progression of small molecule compounds from discovery through to late-stage clinical development and registration. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he had two post-doctoral positions in the AMR area, one in Australia at the University of Queensland and one in Canada at the University of Victoria in British Columbia. He currently serves as the Chief Scientist and Interim Chief of R&D at CARB-X, a global non-profit organization that supports a diverse and innovative pipeline of traditional and non-traditional products to prevent, diagnose, and treat infections caused by drug-resistant bacterial pathogens.